YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
PAVmed Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Optimization Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick.…
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Access Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's ou…
* Lucid Diagnostics press release [https://seekingalpha.com/pr/20618076-lucid-diagnostics-provides-business-update-and-reports-second-quarter-2026-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q2 Non-GAAP EPS of -$0.06…
Alphatec (ATEC) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This…
Globus Medical GMED shares ended the last trading session 5.1% higher at $79.23. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.3% loss over…
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Lucid Diagnostics Inc. (NASDAQ:LUCD) is also on this list of popular penny stocks. TheFly reported on May 15 that Maxim Group reduced its price targe…
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our…
Image source: The Motley Fool. DATE Thursday, May 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Lishan Aklog, M.D. Chief Financial Officer — Dennis McGrath Vice President, Investor Relations — Matthew Ri…
Key Points Interested in Lucid Diagnostics Inc.? Here are five stocks we like better. Lucid Diagnostics reported Q1 2026 EsoGuard test volume of 3,177 and revenue of $1.3 million, with volume still above its pre-Medicare target range despi…
LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items. This…
Earnings Call Insights: Lucid Diagnostics Inc. (LUCD) Q4 2025 MANAGEMENT VIEW * CEO Lishan Aklog reported that "our EsoGuard test volume in the fourth quarter was 3,664. That exceeds our target range that we've articulated regularly of app…
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record Q4 test volume of 3,664, exceeding the target range of 2,500 to 3,000, driven by improved sales team productivity and…
Lucid Diagnostics logo Key Points Lucid reported fourth-quarter EsoGuard test volume of 3,664 (a 29% sequential increase) and $1.5 million in revenue, while noting a billable value of over $9 million and conservative revenue recognition ti…
Image source: The Motley Fool. DATE Thursday, March 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Dr. Lishan Aklog Chief Financial Officer — Dennis M. McGrath Director, Investor Relations — Matthew Riley…
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring item…
The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CMC)is reporting for the quarter ending Febru…
Teleflex (TFX) came out with quarterly earnings of $1.93 per share, missing the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.89 per share a year ago. These figures are adjusted for non-recurring items. This…
Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items. This…
Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter can be downloaded here. In the quarter, Minot Light generated solid returns for limited partners, with a net of 7.…
* Lucid Diagnostics (LUCD [https://seekingalpha.com/symbol/LUCD]) filed for a $175 million mixed securities shelf offering, according to a filing [https://seekingalpha.com/filing/70912804]. * The securities may be offered separately, toget…
In trading on Wednesday, diagnostics shares were relative laggards, down on the day by about 0.4%. Helping drag down the group were shares of Nutex Health, off about 5.7% and shares of Lucid Diagnostics down about 4.1% on the day. Also lag…
* Lucid Diagnostics press release [https://seekingalpha.com/pr/20303744-lucid-diagnostics-provides-business-update-and-reports-third-quarter-2025-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q3 Non-GAAP EPS of -$0.10 m…
Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring…
* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) fell over 17% premarket on Wednesday after it priced a public offering of 25 million shares at $1.00 each. * Underwriters also have a 30-day option to buy up to 3.75…
* Lucid Diagnostics (NASDAQ:LUCD [https://seekingalpha.com/symbol/LUCD]) announced on Tuesday its intention to offer shares [https://seekingalpha.com/pr/20226999-lucid-diagnostics-announces-proposed-public-offering-of-common-stock] of comm…
In recent trading, shares of Karman Holdings Inc (Symbol: KRMN) have crossed above the average analyst 12-month target price of $53.25, changing hands for $54.73/share. When a stock reaches the target an analyst has set, the analyst logica…
Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasia Lucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the te…
Lucidworks, Inc. SAN FRANCISCO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Lucidworks, the leader in AI-powered search and discovery solutions, today announced the recipients of its 2025 Superstars of Search Awards, an annual program recognizing or…
Introduction & Market Context PAVmed Inc. (NASDAQ:PAVM) presented its Q2 2025 business update on August 14, highlighting significant cost reduction measures and progress across its subsidiaries. The medical technology company, currently tr…
Unique to Alameda Point, the Launch Party lane will allow attendees to feel the thrill factor of EVsLucid will offer public demos of their much-anticipated Gravity modelFlying car from Pivotal, hosted by SoFly, will be on displayTesla will…
LUCID DIAGNOSTICS INC (NASDAQ:LUCD [https://www.chartmill.com/stock/quote/LUCD]) reported its second-quarter 2025 financial results, with revenue and earnings per share (EPS) closely aligning with analyst expectations. The company processe…
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that…
Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items. This…
NEW YORK - PAVmed Inc. (NASDAQ:PAVM), a commercial-stage medical technology company with a market capitalization of $10.17 million, announced Wednesday it has received a 180-day extension from Nasdaq to regain compliance with the $1.00 min…
* PAVmed (NASDAQ:PAVM [https://seekingalpha.com/symbol/PAVM]) has been granted a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under the Nasdaq listing rule. * The company now has until January 19, 202…
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary o…